US HB985 | 2019-2020 | 116th Congress
Status
Spectrum: Moderate Partisan Bill (Democrat 4-1)
Status: Introduced on February 5 2019 - 25% progression, died in committee
Action: 2019-02-05 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 5 2019 - 25% progression, died in committee
Action: 2019-02-05 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have competitive access to approved drugs and licensed biological products, so as to enable eligible product developers to develop and test new products, and for other purposes.
Title
FAST Generics Act of 2019 Fair Access for Safe and Timely Generics Act of 2019
Sponsors
Sen. Peter Welch [D-VT] | Rep. David McKinley [R-WV] | Rep. David Cicilline [D-RI] | Rep. Matthew Cartwright [D-PA] |
Rep. Elissa Slotkin [D-MI] |
History
Date | Chamber | Action |
---|---|---|
2019-02-05 | House | Referred to the House Committee on Energy and Commerce. |
2019-02-05 | House | Introduced in House |
Subjects
Competition and antitrust
Drug safety, medical device, and laboratory regulation
Health
Licensing and registrations
Prescription drugs
Drug safety, medical device, and laboratory regulation
Health
Licensing and registrations
Prescription drugs
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/985/all-info |
Text | https://www.congress.gov/116/bills/hr985/BILLS-116hr985ih.pdf |